TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07490496: Phase 3 Bunionectomy Study

Sponsor: Cali Pharmaceuticals LLC · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 112 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07490496 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07490496 Rescue Dossier →